Identification

Name
Latanoprost
Accession Number
DB00654  (APRD01065)
Type
Small Molecule
Groups
Approved, Investigational
Description

Latanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.

It is also known by the brand name of Xalatan manufactured by Pfizer.

Structure
Thumb
Synonyms
  • Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
  • Latanoprost
  • Latanoprostum
  • PhXA 41
  • Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
External IDs
PHXA 41 / PHXA-41 / PHXA41 / T-2345 / T2345 / XA 41 / XA-41 / XA41
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LatanoprostSolution50 mcgOphthalmicActavis Pharma Company2011-10-13Not applicableCanada
Bl LatanoprostSolution50 mcgOphthalmicBausch & Lomb IncNot applicableNot applicableCanada
Gd-latanoprostSolution50 mcgOphthalmicGenmed A Division Of Pfizer Canada Inc2011-10-03Not applicableCanada
Jamp-latanoprostSolution50 mcgOphthalmicJamp Pharma CorporationNot applicableNot applicableCanada
LatanoprostSolution50 mcgOphthalmicLaboratoire Riva IncNot applicableNot applicableCanada
LatanoprostSolution50 ug/mLOphthalmicGreenstone, Llc1995-03-20Not applicableUs
Latanoprost Ophthalmic SolutionSolution50 mcgOphthalmicSandoz Canada IncorporatedNot applicableNot applicableCanada
Med-latanoprostSolution50 mcgOphthalmicGeneric Medical Partners Inc2015-01-09Not applicableCanada
Mint-latanoprostSolution50 mcgOphthalmicMint Pharmaceuticals IncNot applicableNot applicableCanada
MonoprostSolution50 mcgOphthalmicLaboratoires TheaNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-latanoprostSolution50 mcgOphthalmicApotex Corporation2011-10-03Not applicableCanada
LatanoprostSolution / drops50 ug/mLOphthalmicDirectrx2017-03-27Not applicableUs
LatanoprostSolution / drops50 ug/mLOphthalmicMwi2015-04-08Not applicableUs
LatanoprostSolution / drops50 ug/mLOphthalmicRebel Distributors2011-03-22Not applicableUs
LatanoprostSolution / drops50 ug/mLOphthalmicBauch & Lomb Incorporated2011-03-22Not applicableUs
LatanoprostSolution50 ug/mLOphthalmicAmerican Regent2011-08-02Not applicableUs
LatanoprostSolution / drops50 ug/mLOphthalmicA S Medication Solutions2011-03-222017-06-20Us
LatanoprostSolution / drops50 ug/mLOphthalmicAkorn2012-07-01Not applicableUs
LatanoprostSolution / drops50 ug/mLOphthalmicPhysicians Total Care, Inc.2011-06-21Not applicableUs
LatanoprostSolution / drops50 ug/mLOphthalmicA S Medication Solutions2012-07-012017-06-20Us
International/Other Brands
Arulatan (Dr. Gerhard Mann) / Gaap (Sophia) / Gaap Ofteno (Sophia) / Gaax (Chile) / Glaucogesic (Atlas) / Glaumax (Kevelt) / Glauprost (Arrow) / Hysite (Pfizer) / Iopize (SIFI) / Ioprost (FDC) / Ioptame (Cadila) / Klonaprost (Klonal) / Lanoprost (Synpac-Kingdom) / Lanotan (Kuk Je) / Laprost (Oftalmi) / Latacris (Sun-Farm) / Latalux (Jelfa) / Latan-Ophtal (Winzer) / Lataneau (Alapis Pharma) / Xalatan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Latanoprost/timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicActavis Pharma Company2015-09-29Not applicableCanada
Apo-latanoprost-timopLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicApotex Corporation2014-07-02Not applicableCanada
Gd-latanoprost/timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicGenmed A Division Of Pfizer Canada Inc2013-05-01Not applicableCanada
Jamp-latanoprost/timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicJamp Pharma CorporationNot applicableNot applicableCanada
Med-latanoprost-timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicGeneric Medical Partners IncNot applicableNot applicableCanada
Mint-latanoprost/timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-latanoprost/timololLatanoprost (50 mcg) + Timolol (5.0 mg)SolutionOphthalmicMylan PharmaceuticalsNot applicableNot applicableCanada
PMS-latanoprost-timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicPharmascience IncNot applicableNot applicableCanada
Riva-latanoprost/timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicLaboratoire Riva Inc2017-01-03Not applicableCanada
Sandoz Latanoprost/timololLatanoprost (50 mcg) + Timolol (5 mg)SolutionOphthalmicSandoz Canada Incorporated2013-03-04Not applicableCanada
Categories
UNII
6Z5B6HVF6O
CAS number
130209-82-4
Weight
Average: 432.5928
Monoisotopic: 432.28757439
Chemical Formula
C26H40O5
InChI Key
GGXICVAJURFBLW-CEYXHVGTSA-N
InChI
InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
IUPAC Name
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
SMILES
CC(C)OC(=O)CCC\C=C/C[[email protected]]1[[email protected]@H](O)C[[email protected]@H](O)[[email protected]@H]1CC[[email protected]@H](O)CCC1=CC=CC=C1

Pharmacology

Indication

For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Structured Indications
Pharmacodynamics

Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.

Mechanism of action

Latanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

TargetActionsOrganism
AProstaglandin F2-alpha receptor
agonist
Human
Absorption

Latanoprost is well absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form. Peak concentration is reached 2 hrs after topical administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation.

Route of elimination
Not Available
Half life

17 minutes

Clearance
  • 7 mL/min/kg
Toxicity

Symptoms of overdose include bloodshot eyes and eye irritation.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Latanoprost.Experimental
AcebutololLatanoprost may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Acemetacin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
AliskirenLatanoprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Alminoprofen.Experimental
AlprenololLatanoprost may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanLatanoprost may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineLatanoprost may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Latanoprost.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Latanoprost.Approved, Illicit
AndrographolideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Apremilast.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Latanoprost.Approved
AvanafilAvanafil may increase the antihypertensive activities of Latanoprost.Approved
AzapropazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Latanoprost.Approved, Investigational
BendazacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Latanoprost.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Latanoprost.Withdrawn
BenorilateThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Benzydamine.Approved
BepridilLatanoprost may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Latanoprost.Approved
BethanidineBethanidine may increase the hypotensive activities of Latanoprost.Approved
BevoniumThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Latanoprost.Experimental
BimatoprostThe risk or severity of intraocular pressure can be increased when Latanoprost is combined with Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Latanoprost.Approved
BosentanBosentan may increase the hypotensive activities of Latanoprost.Approved, Investigational
BQ-123Latanoprost may increase the hypotensive activities of BQ-123.Investigational
BretyliumLatanoprost may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Latanoprost.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Latanoprost.Experimental
BromfenacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bufexamac.Experimental
BumadizoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bumadizone.Experimental
BupranololLatanoprost may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Latanoprost.Experimental
CafedrineLatanoprost may increase the hypotensive activities of Cafedrine.Investigational
CandesartanLatanoprost may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilLatanoprost may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Latanoprost.Experimental
CaptoprilLatanoprost may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Latanoprost.Withdrawn
CarprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Latanoprost.Approved
CarvedilolLatanoprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololLatanoprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideLatanoprost may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Latanoprost.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineLatanoprost may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilLatanoprost may increase the hypotensive activities of Cilazapril.Approved
ClonidineClonidine may increase the hypotensive activities of Latanoprost.Approved
ClonixinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Clonixin.Approved
CloranololLatanoprost may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineLatanoprost may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideLatanoprost may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Latanoprost.Approved
D-LimoneneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with D-Limonene.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Latanoprost.Approved, Investigational
DelaprilLatanoprost may increase the hypotensive activities of Delapril.Experimental
DeserpidineLatanoprost may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Latanoprost.Approved
DiclofenacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
diethylnorspermineLatanoprost may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Latanoprost.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Latanoprost.Approved
DorzolamideLatanoprost may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Latanoprost.Approved
DroxicamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Latanoprost can be decreased when used in combination with E-6201.Investigational
EfonidipineLatanoprost may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Latanoprost.Approved, Vet Approved
EnalaprilatLatanoprost may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Latanoprost.Experimental
EpanololLatanoprost may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Epirizole.Approved
EpoprostenolLatanoprost may increase the hypotensive activities of Epoprostenol.Approved
EprosartanLatanoprost may increase the hypotensive activities of Eprosartan.Approved
EtanerceptThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Evening primrose oil.Approved, Investigational
exisulindThe therapeutic efficacy of Latanoprost can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Felbinac.Experimental
FelodipineLatanoprost may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Fenbufen.Approved
FenoldopamLatanoprost may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Latanoprost.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Latanoprost.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Latanoprost.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Latanoprost.Approved
GuanazodineLatanoprost may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLatanoprost may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Latanoprost.Approved, Investigational
GuanoclorLatanoprost may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLatanoprost may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLatanoprost may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Latanoprost.Experimental
HexamethoniumLatanoprost may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Latanoprost.Experimental
HydralazineHydralazine may increase the hypotensive activities of Latanoprost.Approved
HydrochlorothiazideLatanoprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideLatanoprost may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Latanoprost.Approved, Investigational
ImidaprilLatanoprost may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Imidazole salicylate.Experimental
IndapamideLatanoprost may increase the hypotensive activities of Indapamide.Approved
IndenololLatanoprost may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Latanoprost.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Latanoprost.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Latanoprost.Withdrawn
IrbesartanLatanoprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Latanoprost.Approved
IsoxicamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Latanoprost.Approved
KebuzoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Latanoprost.Investigational
KetoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Latanoprost.Approved
LacidipineLatanoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
LeflunomideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LinsidomineLatanoprost may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLatanoprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lisofylline.Investigational
LofexidineLatanoprost may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanLatanoprost may increase the hypotensive activities of Losartan.Approved
LoxoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanLatanoprost may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineLatanoprost may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Latanoprost.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Latanoprost.Approved
Meclofenamic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MethoserpidineLatanoprost may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaLatanoprost may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Latanoprost.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Latanoprost.Approved, Investigational
MetipranololLatanoprost may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Latanoprost.Approved
MetoprololMetoprolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
MetyrosineLatanoprost may increase the hypotensive activities of Metyrosine.Approved
MibefradilLatanoprost may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Latanoprost.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Latanoprost.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Latanoprost.Investigational
MizoribineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Latanoprost.Approved
MoexiprilLatanoprost may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Latanoprost.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Latanoprost.Approved, Investigational
MuzolimineLatanoprost may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nabumetone.Approved
NadololLatanoprost may increase the hypotensive activities of Nadolol.Approved
NafamostatThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Naftifine.Approved
NaftopidilLatanoprost may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololLatanoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Latanoprost.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Latanoprost.Approved
NicorandilLatanoprost may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifenazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineLatanoprost may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineLatanoprost may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Latanoprost.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Latanoprost.Approved
NitrendipineLatanoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Latanoprost.Approved
ObinutuzumabLatanoprost may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Latanoprost.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Latanoprost.Approved, Investigational
OlopatadineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Olsalazine.Approved
OmapatrilatLatanoprost may increase the hypotensive activities of Omapatrilat.Investigational
OrgoteinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxaprozin.Approved
OxprenololLatanoprost may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Latanoprost.Approved
ParthenolideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Parthenolide.Investigational
PenbutololLatanoprost may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumLatanoprost may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Latanoprost.Approved, Investigational
PerindoprilLatanoprost may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Latanoprost.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Latanoprost.Withdrawn
PhenoxybenzamineLatanoprost may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Latanoprost.Withdrawn
PhentolamineLatanoprost may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Latanoprost.Withdrawn
PindololLatanoprost may increase the hypotensive activities of Pindolol.Approved
PirfenidoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Latanoprost.Approved
PiroxicamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Latanoprost.Withdrawn
Platelet Activating FactorLatanoprost may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideLatanoprost may increase the hypotensive activities of Polythiazide.Approved
PranoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Latanoprost.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Latanoprost.Approved
ProglumetacinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Proquazone.Experimental
PTC299The therapeutic efficacy of Latanoprost can be decreased when used in combination with PTC299.Investigational
QuinaprilLatanoprost may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Latanoprost.Approved
RamiprilRamipril may increase the hypotensive activities of Latanoprost.Approved
RasagilineRasagiline may increase the hypotensive activities of Latanoprost.Approved
RemikirenRemikiren may increase the hypotensive activities of Latanoprost.Approved
RescinnamineLatanoprost may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Latanoprost.Approved, Investigational
ResveratrolThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Latanoprost.Investigational
RiociguatLatanoprost may increase the hypotensive activities of Riociguat.Approved
RituximabLatanoprost may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Latanoprost.Withdrawn
SalicylamideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salsalate.Approved
SaprisartanLatanoprost may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Latanoprost.Approved, Investigational, Vet Approved
SelexipagLatanoprost may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Serrapeptase.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Latanoprost.Approved, Investigational
SitaxentanLatanoprost may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilLatanoprost may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Latanoprost can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Latanoprost.Approved, Investigational
TalinololLatanoprost may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanLatanoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilLatanoprost may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Teriflunomide.Approved
TerlipressinLatanoprost may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineLatanoprost may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineLatanoprost may increase the hypotensive activities of Theodrenaline.Investigational
Tiaprofenic acidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneLatanoprost may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenLatanoprost may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Latanoprost.Approved
TinoridineThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tinoridine.Investigational
TolazolineLatanoprost may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tolmetin.Approved
TolonidineLatanoprost may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Latanoprost.Approved
TorasemideTorasemide may increase the hypotensive activities of Latanoprost.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Latanoprost.Approved
TranilastThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Latanoprost.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Latanoprost.Approved
TravoprostTravoprost may increase the hypotensive activities of Latanoprost.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Latanoprost.Approved, Investigational
TribenosideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideLatanoprost may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Latanoprost.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Latanoprost.Approved, Investigational
TriptolideThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Latanoprost.Approved, Investigational
UnoprostoneLatanoprost may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Latanoprost.Investigational
ValdecoxibThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Latanoprost.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Latanoprost.Approved
VincamineLatanoprost may increase the hypotensive activities of Vincamine.Experimental
VinpocetineLatanoprost may increase the hypotensive activities of Vinpocetine.Investigational
XipamideLatanoprost may increase the hypotensive activities of Xipamide.Experimental
XylometazolineLatanoprost may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Latanoprost.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilLatanoprost may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Arie Gutman, "Process for the preparation of latanoprost." U.S. Patent US20030149294, issued August 07, 2003.

US20030149294
General References
  1. Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes]. Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. [PubMed:11406947]
External Links
Human Metabolome Database
HMDB14792
KEGG Drug
D00356
PubChem Compound
5311221
PubChem Substance
46506279
ChemSpider
4470740
BindingDB
50240648
ChEBI
6384
ChEMBL
CHEMBL1051
Therapeutic Targets Database
DAP001216
PharmGKB
PA164774763
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Latanoprost
ATC Codes
S01EE01 — Latanoprost
AHFS Codes
  • 52:40.28 — Prostaglandin Analogs
FDA label
Download (502 KB)
MSDS
Download (21.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableGlaucoma / Ocular Hypertension2
1CompletedTreatmentGlaucoma1
1CompletedTreatmentOpen Angle Glaucoma -Ocular Hypertension1
1RecruitingTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
1TerminatedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
1, 2CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
1, 2CompletedTreatmentGlaucoma / Ocular Hypertension1
1, 2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)2
2Active Not RecruitingTreatmentChildhood Glaucoma1
2Active Not RecruitingTreatmentMenière's Disease1
2CompletedScreeningIntraocular Pressure1
2CompletedTreatmentElevated Intraocular Pressure / Glaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
2CompletedTreatmentGlaucoma4
2CompletedTreatmentGlaucoma, Primary Open Angle (POAG)2
2CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension4
2CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension / Pigmentary Glaucoma / Pseudoexfoliative Glaucoma1
2CompletedTreatmentGlaucoma / Glaucoma or Ocular Hypertension and / Ocular Hypertension / Ocular Surface Disease1
2CompletedTreatmentGlaucoma / Ocular Hypertension1
2CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)2
2CompletedTreatmentOcular Hypertension / Open Angle-glaucoma1
2CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)11
2CompletedTreatmentOpen-angle Glaucoma or Ocular Hypertension1
2RecruitingTreatmentOpen-angle Glaucoma, Ocular Hypertension1
2Unknown StatusTreatmentGlaucoma1
2WithdrawnTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
2, 3RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
3Active Not RecruitingTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
3CompletedTreatmentGlaucoma3
3CompletedTreatmentGlaucoma, Angle-Closure / Ocular Hypertension1
3CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension3
3CompletedTreatmentGlaucoma / Ocular Hypertension2
3CompletedTreatmentGlaucoma / Ocular Hypertension / Open Angle Glaucoma (OAG)1
3CompletedTreatmentGlaucoma / Ocular Hypertension / Open-angle Glaucoma (OAG)1
3CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)6
3CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)9
3RecruitingPreventionGlaucoma1
3RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
3RecruitingTreatmentOpen Angle Glaucoma or Ocular Hypertension1
3RecruitingTreatmentPrimary Open Angle Glaucoma or Ocular Hypertension1
3TerminatedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
3Unknown StatusTreatmentGlaucoma1
3WithdrawnTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
3WithdrawnTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedNot AvailableGlaucoma / Ocular Hypertension1
4CompletedNot AvailableOpen-angle Glaucoma (OAG)1
4CompletedBasic ScienceOcular Hypertension / Open Angle Glaucoma (OAG)1
4CompletedSupportive CareDry Eye Syndrome (DES)1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentAnterior Uveitis (AU) / Cystoid Macular Edema1
4CompletedTreatmentApplication Site Pigmentation Changes / Glaucoma1
4CompletedTreatmentEye Diseases / Glaucoma / Open-angle Glaucoma (OAG)1
4CompletedTreatmentGlaucoma8
4CompletedTreatmentGlaucoma / Healthy Volunteers1
4CompletedTreatmentGlaucoma / Ocular Hypertension10
4CompletedTreatmentOcular Hypertension1
4CompletedTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)3
4CompletedTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)8
4CompletedTreatmentOpen-angle Glaucoma (OAG)3
4CompletedTreatmentRetinopathy, Diabetic1
4RecruitingTreatmentGlaucoma1
4RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
4RecruitingTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension / POAG1
4RecruitingTreatmentOcular Hypertension / Open-angle Glaucoma (OAG)1
4TerminatedTreatmentGlaucoma1
4TerminatedTreatmentGlaucoma, Angle-Closure1
4Unknown StatusPreventionGlaucoma / Ocular Hypertension / Thyroid Eye Disease1
4Unknown StatusTreatmentGlaucoma1
4Unknown StatusTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension1
Not AvailableCompletedNot AvailableGlaucoma1
Not AvailableCompletedNot AvailableGlaucoma / Ocular Hypertension2
Not AvailableCompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
Not AvailableCompletedBasic ScienceDrug Effect (Glaucoma Drugs)1
Not AvailableCompletedPreventionRetinopathy, Diabetic1
Not AvailableCompletedTreatmentAlopecia Areata (AA)1
Not AvailableCompletedTreatmentGlaucoma / Ocular Hypertension1
Not AvailableCompletedTreatmentNormal Tension Glaucoma1
Not AvailableCompletedTreatmentPhysiology, Ocular / Retina1
Not AvailableCompletedTreatmentPrimary Vascular Dysregulation1
Not AvailableNot Yet RecruitingTreatmentGlaucoma / IOP / Ocular Hypertension1
Not AvailableRecruitingDiagnosticGlaucoma1
Not AvailableUnknown StatusHealth Services ResearchOpen Angle Glaucoma (OAG)1
Not AvailableUnknown StatusTreatmentGlaucoma1
Not AvailableUnknown StatusTreatmentGlaucoma, Angle-Closure1
Not AvailableUnknown StatusTreatmentOcular Hypertension1
Not AvailableUnknown StatusTreatmentOcular Hypertension / Primary Glaucoma1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic50 ug/mL
Solution / dropsOphthalmic50 ug/mL
SolutionOphthalmic
SolutionOphthalmic50 mcg
Prices
Unit descriptionCostUnit
Xalatan 0.005% Solution 2.5ml Bottle93.59USD bottle
Xalatan 0.005% eye drops45.06USD ml
Xalatan 0.005 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5296504No1994-03-222011-03-22Us
US6429226No1992-09-062009-09-06Us
CA1339132No1997-07-292014-07-29Canada

Properties

State
Liquid
Experimental Properties
PropertyValueSource
water solubility8 mg/mLNot Available
logP4.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0129 mg/mLALOGPS
logP4.16ALOGPS
logP3.98ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)14.47ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability50.71 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9474
Blood Brain Barrier+0.6512
Caco-2 permeable+0.5337
P-glycoprotein substrateSubstrate0.5728
P-glycoprotein inhibitor INon-inhibitor0.8684
P-glycoprotein inhibitor IINon-inhibitor0.7124
Renal organic cation transporterNon-inhibitor0.8805
CYP450 2C9 substrateNon-substrate0.7819
CYP450 2D6 substrateNon-substrate0.8835
CYP450 3A4 substrateSubstrate0.5947
CYP450 1A2 substrateNon-inhibitor0.8845
CYP450 2C9 inhibitorNon-inhibitor0.7724
CYP450 2D6 inhibitorNon-inhibitor0.8985
CYP450 2C19 inhibitorNon-inhibitor0.7236
CYP450 3A4 inhibitorNon-inhibitor0.7393
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7405
Ames testNon AMES toxic0.8324
CarcinogenicityNon-carcinogens0.9379
BiodegradationNot ready biodegradable0.6353
Rat acute toxicity4.3748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9071
hERG inhibition (predictor II)Non-inhibitor0.8763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-052r-1958000000-c694c9459db45a20b9af

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Fatty acid esters / Cyclopentanols / Benzene and substituted derivatives / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Prostaglandin skeleton / Fatty acid ester / Monocyclic benzene moiety / Cyclopentanol / Benzenoid / Cyclic alcohol / Carboxylic acid ester / Secondary alcohol / Carboxylic acid derivative / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carboxylic ester, prostaglandins Falpha, triol (CHEBI:6384)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin f receptor activity
Specific Function
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis...
Gene Name
PTGFR
Uniprot ID
P43088
Uniprot Name
Prostaglandin F2-alpha receptor
Molecular Weight
40054.1 Da
References
  1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. [PubMed:16249494]
  2. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, Hara H: New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003 Dec;26(12):1691-5. [PubMed:14646172]
  3. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004 Apr;78(4):767-76. [PubMed:15037111]
  4. Ocklind A: Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998 Aug;67(2):179-91. [PubMed:9733584]
  5. Maxey KM, Johnson JL, LaBrecque J: The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S34-40. [PubMed:12204699]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Kraft ME, Glaeser H, Mandery K, Konig J, Auge D, Fromm MF, Schlotzer-Schrehardt U, Welge-Lussen U, Kruse FE, Zolk O: The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. doi: 10.1167/iovs.09-4290. Epub 2009 Dec 17. [PubMed:20019365]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34